Inhibition_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
replication_NN
by_IN
a_DT
Tat-activated_JJ
,_,
transduced_VBN
interferon_NN
gene_NN
:_:
targeted_VBN
expression_NN
to_TO
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1-infected_JJ
cells_NNS
._.

We_PRP
have_VBP
examined_VBN
the_DT
feasibility_NN
of_IN
using_VBG
interferon_NN
-LRB-_-LRB-
IFN_NN
-RRB-_-RRB-
gene_NN
transfer_NN
as_IN
a_DT
novel_JJ
approach_NN
to_TO
anti-human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
therapy_NN
in_IN
this_DT
study_NN
._.

To_TO
limit_VB
expression_NN
of_IN
a_DT
transduced_VBN
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
-_:
IFNA2_NN
-LRB-_-LRB-
the_DT
new_JJ
approved_JJ
nomenclature_NN
for_IN
IFN_NN
genes_NNS
is_VBZ
used_VBN
throughout_IN
this_DT
article_NN
-RRB-_-RRB-
hybrid_NN
gene_NN
to_TO
the_DT
HIV-1-infected_JJ
cells_NNS
,_,
HIV-1_NN
LTR_NN
was_VBD
modified_VBN
._.

Deletion_NN
of_IN
the_DT
NF-kappa_NN
B_NN
elements_NNS
of_IN
the_DT
HIV-1_NN
LTR_NN
significantly_RB
inhibited_VBD
Tat-mediated_JJ
transactivation_NN
in_IN
T-cell_NN
lines_NNS
,_,
as_RB
well_RB
as_IN
in_IN
a_DT
monocyte_NN
line_NN
,_,
U937_NN
._.

Replacement_NN
of_IN
the_DT
NF-kappa_NN
B_NN
elements_NNS
in_IN
the_DT
HIV-1_NN
LTR_NN
by_IN
a_DT
DNA_NN
fragment_NN
derived_VBN
from_IN
the_DT
5_CD
'_POS
-_:
flanking_VBG
region_NN
of_IN
IFN-stimulated_JJ
gene_NN
15_CD
-LRB-_-LRB-
ISG15_NN
-RRB-_-RRB-
,_,
containing_VBG
the_DT
IFN-stimulated_JJ
response_NN
element_NN
,_,
partially_RB
restored_VBD
Tat-mediated_JJ
activation_NN
of_IN
LTR_NN
in_IN
T_NN
cells_NNS
as_RB
well_RB
as_IN
in_IN
monocytes_NNS
._.

Insertion_NN
of_IN
this_DT
chimeric_JJ
promoter_NN
-LRB-_-LRB-
ISG15_NN
LTR_NN
-RRB-_-RRB-
upstream_JJ
of_IN
the_DT
human_JJ
IFNA2_NN
gene_NN
directed_VBD
high_JJ
levels_NNS
of_IN
IFN_NN
synthesis_NN
in_IN
Tat-expressing_JJ
cells_NNS
,_,
while_IN
this_DT
promoter_NN
was_VBD
not_RB
responsive_JJ
to_TO
tumor_NN
necrosis_NN
factor_NN
alpha-mediated_JJ
activation_NN
._.

ISG15-LTR-IFN_JJ
hybrid_NN
gene_NN
inserted_VBN
into_IN
the_DT
retrovirus_NN
vector_NN
was_VBD
transduced_VBN
into_IN
Jurkat_NN
and_CC
U937_NN
cells_NNS
._.

Selected_VBN
transfected_VBN
clones_NNS
produced_VBD
low_JJ
levels_NNS
of_IN
IFN_NN
A_NN
-LRB-_-LRB-
IFNA_NN
-RRB-_-RRB-
constitutively_RB
,_,
and_CC
their_PRP$
abilities_NNS
to_TO
express_VB
interleukin-2_NN
and_CC
interleukin-2_NN
receptor_NN
upon_IN
stimulation_NN
with_IN
phytohemagglutinin_NN
and_CC
phorbol_NN
myristate_NN
acetate_NN
were_VBD
retained_VBN
._.

Enhancement_NN
of_IN
IFNA_NN
synthesis_NN
observed_VBN
upon_IN
HIV-1_NN
infection_NN
resulted_VBD
in_IN
significant_JJ
inhibition_NN
of_IN
HIV-1_NN
replication_NN
for_IN
a_DT
period_NN
of_IN
at_IN
least_JJS
30_CD
days_NNS
._.

Virus_NN
isolated_VBN
from_IN
IFNA-producing_JJ
cells_NNS
was_VBD
able_JJ
to_TO
replicate_VB
in_IN
the_DT
U937_NN
cells_NNS
but_CC
did_VBD
not_RB
replicate_VB
efficiently_RB
in_IN
U937_NN
cells_NNS
transduced_VBN
with_IN
the_DT
IFNA_NN
gene_NN
._.

These_DT
results_NNS
suggest_VBP
that_IN
targeting_NN
IFN_NN
synthesis_NN
to_TO
HIV-1-infected_JJ
cells_NNS
is_VBZ
an_DT
attainable_JJ
goal_NN
and_CC
that_IN
autocrine_JJ
IFN_NN
synthesis_NN
results_VBZ
in_IN
a_DT
long-lasting_JJ
and_CC
permanent_JJ
suppression_NN
of_IN
HIV-1_NN
replication_NN
._.

